ALSSI SuperSonic Imagine SA

SuperSonic Imagine to Introduce Aixplorer MACH 30 System for Non-Invasive Management of Liver Disease at The Liver Meeting 2018

SuperSonic Imagine to Introduce Aixplorer MACH 30 System for Non-Invasive Management of Liver Disease at The Liver Meeting 2018

AIX-EN-PROVENCE, France, Nov. 06, 2018 (GLOBE NEWSWIRE) -- SuperSonic Imagine (Euronext: SSI, FR0010526814), a company specializing in ultrasound medical imaging, announced today it will be exhibiting at The Liver Meeting, held at Moscone Center (North and South Halls), San Francisco, November 9–13. During the meeting, held by the American Association for the Study of Liver Diseases (AASLD), SuperSonic Imagine will introduce the Aixplorer MACH® 30, an imaging system that is cleared by the FDA and furthermore the Aixplorer SWE has also been cleared by the FDA as an aid to clinical management of adult and pediatric patients with liver disease such as fibrosis and steatosis.

In addition to routine morphological and hemodynamic imaging, Aixplorer systems can quickly and reliably image and measure liver stiffness in real-time under image guidance, utilizing the platform’s ShearWave® Elastography (SWE) technology, a 60-second non-invasive exam. Liver stiffness is known to be correlated to liver fibrosis severity and is therefore considered a critical non-invasive biomarker of disease severity. A recent clinical study demonstrated that SWE could reduce the need for liver biopsies by 80% in patients with inactive chronic infection1. Aixplorer can also compare ultrasound liver brightness to reference tissue to gain a hepato-renal brightness ratio, which indicates the extent of hepatic steatosis. Aixplorer’s ability to visualize and quantify abdominal vascularization and perfusion aid clinical management of adult patients with liver nodules and advanced chronic liver diseases as well.

The Aixplorer MACH 30 is tailored to meet the needs of liver specialists, it includes the newest version of SuperSonic Imagine’s imaging modes and tools, such as real-time ShearWave Elastography (SWE PLUS), B Mode Ratio to detect intrahepatic steatosis, Angio PL.U.S., which offers unrivalled resolution for imaging microvascularisation in lesions, as well as Doppler and contrast imaging for the screening and characterisation of liver nodules. A new available high-frequency, single-crystal curved transducer is the perfect solution for visualizing narrow intercostal spaces without compromising penetration. The Aixplorer MACH 30’s SonicPad makes exams more efficient, cutting times by up to 32% while allowing physicians to concentrate on the image and the patient, not the controls. SonicPad also uses intuitive gestures to reduce movement by an average 70%.

________________________

1

“We look forward to sharing the Aixplorer MACH 30’s capabilities at this year’s Liver Meeting. Gastroenterologists and Hepatologists will enjoy the enhanced power and improved imaging modes for the assessment of liver fibrosis and NASH severity without a biopsy. Unique ergonomics and improved workflow are just some of the great additions we will be highlighting in our demonstrations,” said SuperSonic Imagine’s Director of North American Sales, Alex Exposito.

Attendees are invited to see demonstrations of the Aixplorer MACH 30 at booth #603.

About SuperSonic Imagine

SuperSonic Imagine specializes in ultrasound medical imaging. The company manufactures the flagship Aixplorer® series of products, which feature the company’s exclusive UltraFast™ technology. UltraFast™ has given rise to new imaging modes that set the standards of care for non-invasive characterization of breast, liver and prostate diseases. The first groundbreaking UltraFast™ mode developed is ShearWave® Elastography (SWE™), which enables doctors to view and instantly analyze tissue stiffness, a vitally important factor in the diagnosis of many conditions. To date, more than 600 published articles have validated the diagnostic value of its technologies.

The most recent addition to the Aixplorer range is the Aixplorer MACH 30® ultrasound platform. It introduces the next generation of UltraFast™ imaging, which optimizes the system’s innovative imaging modes: ShearWave PLUS, Doppler UltraFast™, Angio PL.U.S, TriVu.

The company has more than 2,000 ultrasound systems installed in over 80 countries. Its main growth markets are China, the United States and the European Union (France). The company generated a turnover of €24.7 million in 2017, representing annual growth of 11%. SuperSonic Imagine is listed on Euronext (symbol: SSI).

Find out more at .

Contact information

SuperSonic Imagine

Marketing & Communication

Emmanuelle Vella



27
NewCap

Investor Relations—EU

Pierre Laurent / Thomas Grojean



40
  
FP2COM

Media Relations—EU

Florence Portejoie



83
Pascale Communication

Media Relations—US

Amy Phillips



EN
06/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SuperSonic Imagine SA

 PRESS RELEASE

SuperSonic Imagine annonce la clôture du contrat de liquidité conclu a...

AIX-EN-PROVENCE, France--(BUSINESS WIRE)-- Regulatory News: SuperSonic Imagine (Euronext Growth : ALSSI, FR0010526814, éligible PEA-PME, la « Société »), société spécialisée dans l’imagerie médicale par ultrasons (échographie), annonce la clôture du contrat de liquidité conclu avec Gilbert Dupont Suite l’Offre Publique d’Achat de la société HOLOGIC HUB Ltd sur les actions SUPERSONIC IMAGINE, la société SUPERSONIC IMAGINE met fin au contrat de liquidité conclu le 17 avril 2017 avec la société GILBERT DUPONT. Cette résiliation a pris effet le 28 mai 2021 au soir. A cette date, les moyens suiv...

 PRESS RELEASE

SuperSonic Imagine : Information mensuelle relative au nombre total de...

AIX-EN-PROVENCE, France--(BUSINESS WIRE)-- Regulatory News: SuperSonic Imagine (Paris:ALSSI): Place de cotation: Euronext Growth Compartiment: Compartiment C Code ISIN: FR0010526814 Site web : Date Nombre de titres composant le capital en circulation Nombre total de droits de vote Total brut (1) Total net (2) 31 mai 2021 24 365 850 24 365 850 24 265 118 (1) Le nombre de droits de vote bruts (ou droits de vote “théoriques”) sert de base de calcul pour les franchissements de seuil. Conformément à l’article 223-11 du Règlement Général de l’AMF, ce nombre est ...

 PRESS RELEASE

COMMUNIQUE DE PRESSE DU 26 MAI 2021 RELATIF A LA MISE EN ŒUVRE PAR HOL...

MANCHESTER, Royaume-Uni--(BUSINESS WIRE)-- Regulatory News: Ce communiqué ne constitue pas une offre d’acquérir des titres Ne pas publier, diffuser ou distribuer aux Etats-Unis ou dans tout autre pays que la France COMMUNIQUE DE PRESSE DU 26 MAI 2021 RELATIF A LA MISE EN ŒUVRE PAR HOLOGIC HUB LTD. DU RETRAIT OBLIGATOIRE VISANT LES ACTIONS DE LA SOCIÉTÉ Montant de l’indemnisation : 1,50 euro par action SuperSonic Imagine (net de tous frais) Le présent communiqué est établi et diffusé par la société Hologic Hub Ltd. en application de l’article 237-3 III du Règlement général de l’Autorit...

 PRESS RELEASE

Résultat de l’offre publique d’achat simplifiée initiée par Hologic Hu...

MANCHESTER, Royaume-Uni & AIX-EN-PROVENCE, France--(BUSINESS WIRE)-- Regulatory News: Conformément à l’avis publié ce jour par l’Autorité des marchés financiers (avis AMF D&I n°221C0973), 3 672 579 actions SuperSonic Imagine (Paris:ALSSI) ont été présentées par les actionnaires de SuperSonic Imagine à l’offre publique d’achat simplifiée initiée par Hologic Hub Ltd. libellée au prix de 1,50 euro par action, ouverte du 15 au 30 avril 2021 (inclus) (l’ « Offre »). Hologic Hub Ltd. détiendra, à l’issue des opérations de règlement-livraison, 23 173 992 actions SuperSonic Imagine et autant de droi...

 PRESS RELEASE

Suspension du cours des actions de SuperSonic Imagine sur Euronext Gro...

AIX-EN-PROVENCE, France--(BUSINESS WIRE)-- Regulatory News: SuperSonic Imagine (Euronext Growth : ALSSI, FR0010526814, éligible PEA-PME), société spécialisée dans l’imagerie médicale par ultrasons (échographie) (la « Société »), informe ses actionnaires que la Société a demandé à Euronext Growth Paris la suspension de la cotation de son titre (ALSSI, FR0010526814) à compter de 9h00 ce jour (soit le mardi 4 mai 2021, à l’ouverture de la bourse de Paris), dans l’attente de la publication d’un communiqué de presse annonçant les résultats de l’offre publique d’achat simplifiée initiée par Hologic...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch